Latest news with #NTRA
Yahoo
2 days ago
- Business
- Yahoo
3 Mid-Cap Stocks Worth Your Attention
Large trillion-dollar companies are tightening their grip on the market, often by acquiring smaller rivals. This trend will likely pick up with new regulatory leadership, but a few mid-sized businesses will continue prospering by anchoring themselves in unique market segments. Digging up these buried treasures isn't easy, and that's exactly why we created StockStory. That said, here are three of our favorite mid-cap stocks that could amplify your portfolio's returns. Market Cap: $15.99 billion Playing on the secular trend of healthier living, Sprouts Farmers Market (NASDAQ:SFM) is a grocery store chain emphasizing natural and organic products. Why Do We Watch SFM? Aggressive strategy of rolling out new stores to gobble up whitespace is prudent given its same-store sales growth Comparable store sales rose by 6.6% on average over the past two years, demonstrating its ability to drive increased spending at existing locations Free cash flow margin grew by 2.1 percentage points over the last year, giving the company more chips to play with Sprouts is trading at $163 per share, or 33.6x forward P/E. Is now the time to initiate a position? See for yourself in our comprehensive research report, it's free. Market Cap: $20.94 billion Founded in 2003 as Gene Security Network before rebranding in 2012, Natera (NASDAQ:NTRA) develops and commercializes genetic tests for prenatal screening, cancer detection, and organ transplant monitoring using its proprietary cell-free DNA technology. Why Is NTRA a Good Business? Products are reaching more customers as its tests processed averaged 23.1% growth over the past two years Adjusted operating profits and efficiency rose over the last two years as it benefited from some fixed cost leverage Free cash flow profile has moved into positive territory over the last five years, showing the company has crossed a key inflection point Natera's stock price of $153.89 implies a valuation ratio of 10.1x forward price-to-sales. Is now the right time to buy? Find out in our full research report, it's free. Market Cap: $13.39 billion With roots dating back to 1914 and deep ties to nearly all U.S. cabinet-level departments, Booz Allen Hamilton (NYSE:BAH) provides management consulting, technology services, and cybersecurity solutions primarily to U.S. government agencies and military branches. Why Are We Backing BAH? Market share has increased this cycle as its 13.7% annual revenue growth over the last two years was exceptional Existing business lines can expand without risky acquisitions as its organic revenue growth averaged 12.9% over the past two years Share repurchases have amplified shareholder returns as its annual earnings per share growth of 14.9% exceeded its revenue gains over the last five years At $108.40 per share, Booz Allen Hamilton trades at 15.7x forward P/E. Is now a good time to buy? See for yourself in our in-depth research report, it's free. Donald Trump's victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs. While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today for free.
Yahoo
20-05-2025
- Business
- Yahoo
Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
Launched on 06/23/2005, the Invesco Biotechnology & Genome ETF (PBE) is a smart beta exchange traded fund offering broad exposure to the Health Care ETFs category of the market. The ETF industry has traditionally been dominated by products based on market capitalization weighted indexes that are designed to represent the market or a particular segment of the market. Because market cap weighted indexes provide a low-cost, convenient, and transparent way of replicating market returns, they work well for investors who believe in market efficiency. On the other hand, some investors who believe that it is possible to beat the market by superior stock selection opt to invest in another class of funds that track non-cap weighted strategies--popularly known as smart beta. These indexes attempt to select stocks that have better chances of risk-return performance, based on certain fundamental characteristics or a combination of such characteristics. Methodologies like equal-weighting, one of the simplest options out there, fundamental weighting, and volatility/momentum based weighting are all choices offered to investors in this space, but not all of them can deliver superior returns. Managed by Invesco, PBE has amassed assets over $222.17 million, making it one of the average sized ETFs in the Health Care ETFs. Before fees and expenses, PBE seeks to match the performance of the Dynamic Biotechnology & Genome Intellidex Index. The Dynamic Biotech & Genome Intellidex Index seeks to provide capital appreciation by thoroughly evaluating companies based on a variety of investment merit criteria, including price momentum, earnings momentum, quality, management action, and value. Investors should also pay attention to an ETF's expense ratio. Lower cost products will produce better results than those with a higher cost, assuming all other metrics remain the same. Operating expenses on an annual basis are 0.58% for this ETF, which makes it on par with most peer products in the space. It's 12-month trailing dividend yield comes in at 0.07%. It is important to delve into an ETF's holdings before investing despite the many upsides to these kinds of funds like diversified exposure, which minimizes single stock risk. And, most ETFs are very transparent products that disclose their holdings on a daily basis. Representing 99.80% of the portfolio, the fund has heaviest allocation to the Healthcare sector. Taking into account individual holdings, Natera Inc (NTRA) accounts for about 5.34% of the fund's total assets, followed by Neurocrine Biosciences Inc (NBIX) and Gilead Sciences Inc (GILD). PBE's top 10 holdings account for about 45.87% of its total assets under management. So far this year, PBE has lost about -5.51%, and is down about -2.67% in the last one year (as of 05/20/2025). During this past 52-week period, the fund has traded between $56.01 and $72.24. The ETF has a beta of 0.79 and standard deviation of 22.19% for the trailing three-year period, making it a high risk choice in the space. With about 32 holdings, it has more concentrated exposure than peers. Invesco Biotechnology & Genome ETF is a reasonable option for investors seeking to outperform the Health Care ETFs segment of the market. However, there are other ETFs in the space which investors could consider. SPDR S&P Biotech ETF (XBI) tracks S&P Biotechnology Select Industry Index and the iShares Biotechnology ETF (IBB) tracks Nasdaq Biotechnology Index. SPDR S&P Biotech ETF has $4.88 billion in assets, iShares Biotechnology ETF has $5.27 billion. XBI has an expense ratio of 0.35% and IBB charges 0.45%. Investors looking for cheaper and lower-risk options should consider traditional market cap weighted ETFs that aim to match the returns of the Health Care ETFs. To learn more about this product and other ETFs, screen for products that match your investment objectives and read articles on latest developments in the ETF investing universe, please visit Zacks ETF Center. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Invesco Biotechnology & Genome ETF (PBE): ETF Research Reports Gilead Sciences, Inc. (GILD) : Free Stock Analysis Report iShares Biotechnology ETF (IBB): ETF Research Reports Neurocrine Biosciences, Inc. (NBIX) : Free Stock Analysis Report SPDR S&P Biotech ETF (XBI): ETF Research Reports Natera, Inc. (NTRA) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Egypt Today
20-05-2025
- Egypt Today
NTRA launches new rules to regulate telemarketers and spam calls
Cairo – May 20, 2025: The National Telecommunications Regulatory Authority (NTRA) has unveiled a new set of regulatory and technical measures aimed at increasing transparency in communications and giving users greater control over incoming calls. The initiative focuses on helping citizens better identify callers—whether through mobile or landline phones—and marks a major step in the ongoing fight against nuisance and promotional calls. The NTRA announced the changes in a press release on Monday, emphasizing that the updates are part of broader efforts to protect the privacy of telecommunications users and to tackle persistent disturbances caused by unsolicited calls. One of the key updates is the launch of a caller ID feature for landline phones, which allows users to view the name of the calling party—including entities making promotional calls—before answering. The measure is expected to help individuals make informed decisions about which calls to accept. In a further upgrade, the caller identification system has been expanded to display not just the caller's name but also their role or occupation. This is particularly relevant for calls coming from journalists, delivery service personnel, or individuals working in donation campaigns. The enhancement aims to distinguish such legitimate calls from unwanted telemarketing attempts. The NTRA has also outlined tough penalties for violations. Any device found to be using unregistered lines for promotional calls more than once to make nuisance calls will be deactivated across all networks in Egypt. In cases where the user attempts to bypass the restriction by reactivating the device with another unregistered line and continues making nuisance calls, the phone will be permanently blocked and rendered inoperable on any Egyptian telecom network. Additionally, individuals proven to have used unauthorized lines for marketing purposes will be permanently banned from obtaining new lines, even for personal use. The regulator said this step is crucial to ensuring adherence to its privacy-protection framework. These new rules build on earlier regulations issued in July 2024, which required anyone making promotional or commercial calls to register their details with mobile operators and legally activate the relevant service. Under those rules, callers must also ensure that recipients are informed of the nature of the call, either through the display of the entity's name or a prior warning label such as 'NTRA Alert.' The authority stressed its commitment to strict enforcement and ongoing collaboration with telecom providers to uphold these measures. Citizens are also encouraged to report any violations or nuisance calls through telecom operators' customer service channels or directly via the NTRA's call center. The move is seen as a significant advancement in regulating Egypt's telecommunications environment and reflects growing demand for better consumer protection in the face of rising privacy concerns.
Yahoo
15-05-2025
- Business
- Yahoo
Seagate Technology Holdings PLC: A Significant Reduction in Stanley Druckenmiller's Portfolio
Warning! GuruFocus has detected 3 Warning Signs with NTRA. Stanley Druckenmiller (Trades, Portfolio) recently submitted the 13F filing for the first quarter of 2025, providing insights into his investment moves during this period. Stanley Druckenmiller (Trades, Portfolio), born in 1953 in Pittsburgh, Pennsylvania, is the President, CEO, and Chairman of Duquesne Capital, which he founded in 1981 and converted into a family office in 2010. He managed money for George Soros (Trades, Portfolio) from 1988 to 2000 as the lead portfolio manager for Quantum Fund. The two partners famously shorted the British Pound in 1992. Druckenmiller was highly influenced by George Soros (Trades, Portfolio)' trading style, which is quite evident in his own investing strategy. He uses a top-down approach that combines long positions and short positions in all types of assets like stocks, bonds, currencies, and futures. Stanley Druckenmiller (Trades, Portfolio) added a total of 12 stocks, among them: The most significant addition was Docusign Inc (NASDAQ:DOCU), with 1,074,655 shares, accounting for 2.86% of the portfolio and a total value of $87.48 million. The second largest addition to the portfolio was CCC Intelligent Solutions Holdings Inc (NASDAQ:CCCS), consisting of 5,595,039 shares, representing approximately 1.65% of the portfolio, with a total value of $50.52 million. The third largest addition was EQT Corp (NYSE:EQT), with 859,345 shares, accounting for 1.5% of the portfolio and a total value of $45.92 million. Stanley Druckenmiller (Trades, Portfolio) also increased stakes in a total of 14 stocks, among them: The most notable increase was Teva Pharmaceutical Industries Ltd (NYSE:TEVA), with an additional 5,882,350 shares, bringing the total to 14,879,750 shares. This adjustment represents a significant 65.38% increase in share count, a 2.95% impact on the current portfolio, with a total value of $228.7 million. The second largest increase was Taiwan Semiconductor Manufacturing Co Ltd (NYSE:TSM), with an additional 491,265 shares, bringing the total to 598,780. This adjustment represents a significant 456.93% increase in share count, with a total value of $99.4 million. Stanley Druckenmiller (Trades, Portfolio) completely exited 37 holdings in the first quarter of 2025, as detailed below: Skechers USA Inc (NYSE:SKX): Stanley Druckenmiller (Trades, Portfolio) sold all 1,074,840 shares, resulting in a -1.94% impact on the portfolio. SLM Corp (NASDAQ:SLM): Stanley Druckenmiller (Trades, Portfolio) liquidated all 2,520,275 shares, causing a -1.87% impact on the portfolio. Stanley Druckenmiller (Trades, Portfolio) also reduced positions in 17 stocks. The most significant changes include: Reduced Seagate Technology Holdings PLC (NASDAQ:STX) by 1,344,599 shares, resulting in an -85.97% decrease in shares and a -3.12% impact on the portfolio. The stock traded at an average price of $94.51 during the quarter and has returned 6.74% over the past 3 months and 25.49% year-to-date. Reduced United Airlines Holdings Inc (NASDAQ:UAL) by 675,120 shares, resulting in a -64.68% reduction in shares and a -1.76% impact on the portfolio. The stock traded at an average price of $94.43 during the quarter and has returned -26.59% over the past 3 months and -21.17% year-to-date. At the first quarter of 2025, Stanley Druckenmiller (Trades, Portfolio)'s portfolio included 52 stocks. The top holdings included 15.72% in Natera Inc (NASDAQ:NTRA), 7.47% in Teva Pharmaceutical Industries Ltd (NYSE:TEVA), 6.67% in Coupang Inc (NYSE:CPNG), 6.55% in Woodward Inc (NASDAQ:WWD), and 5.73% in Philip Morris International Inc (NYSE:PM). The holdings are mainly concentrated in 9 of all the 11 industries: Healthcare, Technology, Consumer Cyclical, Industrials, Energy, Consumer Defensive, Financial Services, Basic Materials, and Communication Services. This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13-05-2025
- Business
- Yahoo
Natera, Inc. (NTRA): A Bull Case Theory
We came across a bullish thesis on Natera, Inc. (NTRA) on Substack by FJ Research. In this article, we will summarize the bulls' thesis on NTRA. Natera, Inc. (NTRA)'s share was trading at $162.57 as of May 8th. A doctor in a medical laboratory wearing a protective suit and a face mask, running a molecular diagnostic test. Natera is emerging as one of the most pivotal companies in the transformation of global healthcare, and its significance has not gone unnoticed by legendary investor Stanley Druckenmiller—who has made it his largest position. Known for his nearly unmatched track record, including 30%+ annual returns over decades and prescient bets on tech, AI, and energy, Druckenmiller only invests his own capital and swings hard when the upside far outweighs the risk. His conviction in Natera is a signal worth paying close attention to. When someone with his foresight and discipline makes such a concentrated bet, it suggests the company's long-term potential may be vastly underappreciated by the broader market. Natera specializes in non-invasive, DNA-based diagnostic testing with a mission to shift healthcare from reactive treatment to proactive detection. Its key platforms—Signatera™ for monitoring cancer recurrence, Prospera™ for transplant rejection, and Panorama™ for prenatal screening—are category-defining technologies. These aren't incremental improvements; they're transformative solutions targeting massive, underserved markets. Signatera leads in the fast-growing minimal residual disease (MRD) space, helping detect cancer recurrence earlier than traditional methods. Prospera offers real-time organ transplant health monitoring, while Panorama is already widely used in prenatal care. Together, these platforms could reshape how millions are diagnosed and treated. The company is growing rapidly, backed by years of research and clinical validation. Natera's diagnostics are gaining traction in mainstream medical practice, and institutional confidence is high—early backing from Sequoia Capital reinforces its credibility. Beyond technology, Natera's founding story adds emotional weight to its mission. Founder Matthew Rabinowitz launched the company after losing a family member to a preventable genetic condition, fueling his drive to bring early detection into the medical mainstream. That personal origin is reflected in the company's culture and long-term vision. Despite operating in a highly technical and regulated industry, Natera's business is increasingly about inevitability. AI and computational biology are finally disrupting healthcare, and Natera is at the center of this shift. The company's addressable market is vast, especially in oncology, where early detection can dramatically improve outcomes and lower costs. For investors, this represents a rare opportunity: a company with real-world impact, strong growth, deep competitive moats, and the endorsement of one of the greatest investors of our time. Druckenmiller's high-conviction bet highlights what's at stake—and why Natera may be one of the most essential and undervalued healthcare companies of the next decade. Natera, Inc. (NTRA) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 77 hedge fund portfolios held NTRA at the end of the fourth quarter which was 62 in the previous quarter. While we acknowledge the risk and potential of NTRA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than NTRA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey.
